Skip to main content
Erschienen in: Clinical Drug Investigation 3/2016

01.03.2016 | Original Research Article

The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy

verfasst von: Gianluca Trifirò, Fabrizio Parrino, Valeria Pizzimenti, Francesco Giorgianni, Janet Sultana, Marco Muscianisi, Chiara Troncone, Daniele U. Tari, Vincenzo Arcoraci, Domenico Santoro, Giusi Russo, Viviana Lacava, Achille P. Caputi

Erschienen in: Clinical Drug Investigation | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Diabetes mellitus in patients with chronic kidney disease (CKD) is known as diabetic kidney disease (DKD). Pharmacological management of DKD is challenging due to reduced renal excretion of some antidiabetic drugs. The aim of this population-based study was to explore antidiabetic drug use in DKD patients from Southern Italy.

Methods

The Arianna database from Caserta Local Health Unit was used. Diabetic patients with incident CKD [first diagnosis date: index date (ID)] were identified by searching for specific ICD9-CM codes among hospital discharge diagnoses/procedures and/or indication of use associated with drug prescriptions. To evaluate any change in the use of antidiabetic drugs after the CKD diagnosis, the prevalence of antidiabetic drug use among DKD patients was calculated within 1 year prior to/after ID and after dialysis entry. A Kaplan–Meier analysis was used to assess the time to discontinuation of antidiabetic drugs after CKD diagnosis. The frequency of antidiabetic drugs contraindicated in renal disease in DKD patients was measured.

Results

Overall, 725 diabetic patients (mean age 72.8 ± 11.4 years) had incident CKD from 2006 to 2011. The use of combination antidiabetic drugs, biguanides and sulphonamides decreased by approximately 10, 7 and 5 %, respectively, after the ID. The use of insulins increased by 10 % after the ID and by 20 % after entry into dialysis. The use of antidiabetic drugs not contraindicated in CKD decreased marginally after the diagnosis of CKD.

Conclusion

In a general practice of Southern Italy the management of diabetes mellitus changed only marginally in newly diagnosed CKD patients, suggesting a therapeutic inertia on the part of prescribers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228–36.CrossRefPubMed Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228–36.CrossRefPubMed
5.
Zurück zum Zitat Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes. 2007;25:90–7.CrossRef Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes. 2007;25:90–7.CrossRef
7.
Zurück zum Zitat Panzetta G, Basile C, Santoro A, Ancarani E, Costantini S, Guarnieri F, et al. Diabetics on dialysis in Italy: a nationwide epidemiological study. Nephrol Dial Transpl. 2008;23:3988–95.CrossRef Panzetta G, Basile C, Santoro A, Ancarani E, Costantini S, Guarnieri F, et al. Diabetics on dialysis in Italy: a nationwide epidemiological study. Nephrol Dial Transpl. 2008;23:3988–95.CrossRef
8.
Zurück zum Zitat Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M, et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and non-coronary events in patients with type 2 diabetes—the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Care. 2012;35(1):143–9.PubMedCentralCrossRefPubMed Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Arosio M, et al. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and non-coronary events in patients with type 2 diabetes—the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Care. 2012;35(1):143–9.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Pugliese G, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutr Metab Cardiovasc Dis. 2014;24(8):815–22.CrossRefPubMed Pugliese G, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutr Metab Cardiovasc Dis. 2014;24(8):815–22.CrossRefPubMed
10.
Zurück zum Zitat National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–86.CrossRef National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–86.CrossRef
11.
Zurück zum Zitat Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382–91.CrossRefPubMed Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382–91.CrossRefPubMed
12.
Zurück zum Zitat Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis. 2014;63(2 Suppl 2):S22–38.CrossRefPubMed Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis. 2014;63(2 Suppl 2):S22–38.CrossRefPubMed
13.
Zurück zum Zitat Piacentini N, Trifirò G, Tari M, Moretti S, Arcoraci V. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol. 2005;61(8):615–20.CrossRefPubMed Piacentini N, Trifirò G, Tari M, Moretti S, Arcoraci V. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol. 2005;61(8):615–20.CrossRefPubMed
14.
Zurück zum Zitat Trifirò G, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol. 2006;62(5):582–90.PubMedCentralCrossRefPubMed Trifirò G, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol. 2006;62(5):582–90.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Alacqua M, Trifirò G, Cavagna L, Caporali R, Montecucco CM, Moretti S, et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum. 2008;59(4):568–74.CrossRefPubMed Alacqua M, Trifirò G, Cavagna L, Caporali R, Montecucco CM, Moretti S, et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum. 2008;59(4):568–74.CrossRefPubMed
16.
Zurück zum Zitat Oteri A, Trifirò G, Gagliostro MS, Tari DU, Moretti S, Bramanti P, et al. Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004–07. Br J Clin Pharmacol. 2010;70(4):514–22.PubMedCentralCrossRefPubMed Oteri A, Trifirò G, Gagliostro MS, Tari DU, Moretti S, Bramanti P, et al. Prescribing pattern of anti-epileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004–07. Br J Clin Pharmacol. 2010;70(4):514–22.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Ferrajolo C, Arcoraci V, Sullo MG, Rafaniello C, Sportiello L, Ferrara R, et al. Pattern of statin use in Southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One. 2014;9(7):e102146.PubMedCentralCrossRefPubMed Ferrajolo C, Arcoraci V, Sullo MG, Rafaniello C, Sportiello L, Ferrara R, et al. Pattern of statin use in Southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One. 2014;9(7):e102146.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Rafaniello C, Arcoraci V, Ferrajolo C, Sportiello L, Sullo MG, Giorgianni F, et al. Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study. Diabetes Res Clin Pract. 2015;108(1):157–63.CrossRefPubMed Rafaniello C, Arcoraci V, Ferrajolo C, Sportiello L, Sullo MG, Giorgianni F, et al. Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: a population-based study. Diabetes Res Clin Pract. 2015;108(1):157–63.CrossRefPubMed
19.
Zurück zum Zitat Trifirò G, Sultana J, Giorgianni F, Ingrasciotta Y, Buemi M, Muscianisi M, et al. Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. Biomed Res Int. 2014;2014:268362.PubMedCentralCrossRefPubMed Trifirò G, Sultana J, Giorgianni F, Ingrasciotta Y, Buemi M, Muscianisi M, et al. Chronic kidney disease requiring healthcare services: a new approach to evaluate epidemiology of renal disease. Biomed Res Int. 2014;2014:268362.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Ingrasciotta Y, Sultana J, Giorgianni F, Fontana A, Santangelo A, Tari DU, Santoro D, Arcoraci V, Perrotta M, Ibanez L, Trifirò G. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015;10(4):e0122899.PubMedCentralCrossRefPubMed Ingrasciotta Y, Sultana J, Giorgianni F, Fontana A, Santangelo A, Tari DU, Santoro D, Arcoraci V, Perrotta M, Ibanez L, Trifirò G. Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015;10(4):e0122899.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Sultana J, Musazzi UM, Ingrasciotta Y, Giorgianni F, Ientile V, Fontana A, Minghetti P, Perrotta M, Santoro D, Savica V, Trifirò G. Medication is an additional source of phosphate intake in chronic kidney disease patients. Nutr Metab Cardiovasc Dis. 2015;25(10):959–67.CrossRefPubMed Sultana J, Musazzi UM, Ingrasciotta Y, Giorgianni F, Ientile V, Fontana A, Minghetti P, Perrotta M, Santoro D, Savica V, Trifirò G. Medication is an additional source of phosphate intake in chronic kidney disease patients. Nutr Metab Cardiovasc Dis. 2015;25(10):959–67.CrossRefPubMed
22.
Zurück zum Zitat Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014;9(2):e89072.PubMedCentralCrossRefPubMed Ingrasciotta Y, Sultana J, Giorgianni F, Caputi AP, Arcoraci V, Tari DU, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014;9(2):e89072.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20(6):925–8.CrossRefPubMed Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20(6):925–8.CrossRefPubMed
24.
Zurück zum Zitat Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12(1):57–69.CrossRefPubMed Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011;12(1):57–69.CrossRefPubMed
25.
Zurück zum Zitat Libardi F, Sirolli V, Cappelli P, Bonomini M. Farmaci ipoglicemizzanti orali nei pazienti con insufficienza renale cronica. G Ital Nefrol. 2009;26(6):679–85.PubMed Libardi F, Sirolli V, Cappelli P, Bonomini M. Farmaci ipoglicemizzanti orali nei pazienti con insufficienza renale cronica. G Ital Nefrol. 2009;26(6):679–85.PubMed
26.
Zurück zum Zitat KDOQI clinical practice guideline for diabetes and CKD: 2012 update. National Kidney Foundations. Am J Kidney Dis. 2012;850–886. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. National Kidney Foundations. Am J Kidney Dis. 2012;850–886.
27.
Zurück zum Zitat Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.PubMedCentralCrossRefPubMed Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.PubMedCentralCrossRefPubMed
28.
29.
Zurück zum Zitat Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75:1487–96.PubMed Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75:1487–96.PubMed
30.
Zurück zum Zitat Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000;35:500–5.CrossRefPubMed Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000;35:500–5.CrossRefPubMed
31.
Zurück zum Zitat Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006;70:1223–33.CrossRefPubMed Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006;70:1223–33.CrossRefPubMed
32.
Zurück zum Zitat Mohideen P, Bornemann M, Sugihara J, Genadio V, Sugihara V, Arakaki R. The metabolic effects of troglitazone in patients with diabetes and endstage renal disease. Endocrine. 2005;28(2):181–6.CrossRefPubMed Mohideen P, Bornemann M, Sugihara J, Genadio V, Sugihara V, Arakaki R. The metabolic effects of troglitazone in patients with diabetes and endstage renal disease. Endocrine. 2005;28(2):181–6.CrossRefPubMed
33.
Zurück zum Zitat Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–70.CrossRefPubMed Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004;17:365–70.CrossRefPubMed
34.
Zurück zum Zitat Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–90.CrossRefPubMed Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–90.CrossRefPubMed
35.
Zurück zum Zitat Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123(3):133–43.CrossRefPubMed Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123(3):133–43.CrossRefPubMed
36.
Zurück zum Zitat Fabbian F, De Giorgi A, Monesi M, Tiseo R, Storari A, Mallozzi Menegatti A, et al. Prescription of oral antidiabetic drugs in K/DIGO chronic kidney disease stage 3 and 4: a single centre report. Minerva Urol Nefrol. 2014;66(1):69–75.PubMed Fabbian F, De Giorgi A, Monesi M, Tiseo R, Storari A, Mallozzi Menegatti A, et al. Prescription of oral antidiabetic drugs in K/DIGO chronic kidney disease stage 3 and 4: a single centre report. Minerva Urol Nefrol. 2014;66(1):69–75.PubMed
37.
Zurück zum Zitat Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc Health Risk Manag. 2014;10:341–52.PubMedCentralPubMed Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc Health Risk Manag. 2014;10:341–52.PubMedCentralPubMed
38.
Zurück zum Zitat De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, et al. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transpl. 2014;29(3):657–62.CrossRef De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, et al. Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transpl. 2014;29(3):657–62.CrossRef
39.
Zurück zum Zitat Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;20(3):280 e1–7. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;20(3):280 e1–7.
40.
Zurück zum Zitat Arcoraci V, Santoni L, Ferrara R, Furneri G, Cannata A, Sultana J, et al. Effect of an educational program in primary care: the case of lipid control in cardio-cerebrovascular prevention. Int J Immunopathol Pharmacol. 2014;27(3):351–63.PubMed Arcoraci V, Santoni L, Ferrara R, Furneri G, Cannata A, Sultana J, et al. Effect of an educational program in primary care: the case of lipid control in cardio-cerebrovascular prevention. Int J Immunopathol Pharmacol. 2014;27(3):351–63.PubMed
Metadaten
Titel
The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy
verfasst von
Gianluca Trifirò
Fabrizio Parrino
Valeria Pizzimenti
Francesco Giorgianni
Janet Sultana
Marco Muscianisi
Chiara Troncone
Daniele U. Tari
Vincenzo Arcoraci
Domenico Santoro
Giusi Russo
Viviana Lacava
Achille P. Caputi
Publikationsdatum
01.03.2016
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 3/2016
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.1007/s40261-015-0367-6

Weitere Artikel der Ausgabe 3/2016

Clinical Drug Investigation 3/2016 Zur Ausgabe